by Camila Londono | Oct 25, 2016
The fifth Till & McCulloch Meetings started off with a bang, with an incredibly exciting and provocative talk by Dr. Sara-Jane Dunn that highlighted the predictive power of Boolean network models. Dr. Dunn, who works at Microsoft Research, introduced the idea of...
by Camila Londono | Oct 14, 2016
On October 11 I attended SHE DID THAT, the Ada Lovelace event, held at the University of Toronto, that Samantha Payne wrote about in Signals earlier this week. It was an exciting evening that not only celebrated incredible women in science, but also served as a...
by Lisa Willemse | Sep 30, 2016
There’s nothing really funny about the patent debate on CRISPR-Cas9 gene editing. It’s been a contentious and expensive court battle, that has thankfully steered clear of mud-slinging (mostly). Which is good, since there’s more than enough of that in the U.S. these...
by Michael May | Aug 30, 2016
Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into...
by David Kent | Aug 25, 2016
One of the most memorable moments of my young scientist career was a Keystone Conference in February 2006 in Whistler, BC where I first heard Professor Shinya Yamanaka describe the successful reprogramming of a skin cell into an induced pluripotent stem cell (iPSC)....
Comments